Join a Clinical Trial

The FROST study is focused on exploring cryoablation as a non-surgical treatment option for women with early-stage breast cancer. Cryoablation involves freezing the tumor tissue using a cryoprobe, which is guided by ultrasound. This procedure is designed to target and destroy the tumor while preserving healthy surrounding tissue. The primary objective of the study is to determine the rate of successful tumor ablation and to monitor patients for recurrence over a period of five years. The study also aims to evaluate cosmetic outcomes and any potential adverse effects associated with the procedure.

The FROST Study is only open for follow-up of previously treatment patients. The study is NOT open to enrollment of additional patients.

The FROST Study is only open for follow-up of previously treatment patients. The study is NOT open to enrollment of additional patients.

This study explores cryoablation as an innovative, non-surgical treatment for ductal carcinoma in situ (DCIS). Cryoablation involves freezing the tumor using a cryoprobe, which is guided to the lesion through ultrasound. This procedure is office-based and performed under local anesthesia, minimizing the physical and psychological burden associated with traditional surgery. The primary goal is to determine if cryoablation can effectively ablate all DCIS within the targeted area, potentially offering a less invasive treatment option for patients.

• DCIS measuring 2 cm or less based on mammography or breast MRI.
• Confirmed diagnosis of DCIS through minimally invasive needle biopsy.
• No prior history of DCIS or invasive breast cancer in the same breast.
• No prior surgical biopsy or lumpectomy in the same breast.
• Adequate breast volume and skin clearance for safe cryoablation.
• Non-pregnant, non-lactating, and no pregnancy in the last 6 months.
• No history of breast radiation in the same breast.